ReviewFrontiers in endocrinology2022
COVID-19 and diabetes-Two giants colliding: From pathophysiology to management.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- SARS-CoV-2 and diabetes: a post-pandemic reappraisal.Diabetologia · 2026Review
- Effect of Baseline HbA1c and Inpatient Glycemic Control on Mortality and Organ Dysfunction among Patients with Diabetes Mellitus Hospitalized for COVID-19: A Multicenter Retrospective Cohort Study.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Long term cardiometabolic outcomes in COVID positive patients.Journal of public health research · 2026Review
- New insights into the role of metallothioneins in obesity and diabetes.International journal of obesity (2005) · 2025Review
- Current Landscape of the Interrelationship Between Periodontitis, Type 2 Diabetes Mellitus, and COVID-19.International journal of molecular sciences · 2025Review
- Comparative Analysis of COVID-19 Outcomes in Type 1 and Type 2 Diabetes: A Three-Year Retrospective Study.Medicina (Kaunas, Lithuania) · 2024Article
- Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.Frontiers in pharmacology · 2024Article
- Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19).Diabetology & metabolic syndrome · 2023Article
- Diabetes in all hospitalized cases in Germany 2015-2019 and impact of the first COVID-19 year 2020.Endocrine connections · 2023Article
- Insight on Infections in Diabetic Setting.Biomedicines · 2023Review
- Clinical characteristics and acute complication of COVID-19 patients with diabetes: a multicenter, retrospective study in Southern China.Frontiers in endocrinology · 2023Article
- Exploring transfer learning in chest radiographic images within the interplay between COVID-19 and diabetes.Frontiers in public health · 2023Article
- Estimating causal effects of genetically predicted type 2 diabetes on COVID-19 in the East Asian population.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since December 2019, a new coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread around the world, causing the coronavirus 2019 (COVID-19) pandemic. From the beginning, SARS-CoV-2 has put a strain on the health system. In fact, many patients have had severe forms of the disease with the need for hospitalization due to respiratory failure. To contain the pandemic, the most widely used approach has been lockdowns. Social restrictions have been reduced thanks to the development of vaccines and targeted therapies. However, fatal events still occur among people at high risk of serious infection, such as patients with concomitant diabetes. Different mechanisms have been proposed to explain the poor prognosis of patients with diabetes and COVID-19, but the specific cause is unclear. It is now known that insulin resistance, inflammation, and cytokine storm are involved. Moreover, SARS-CoV-2 uses the angiotensin-converting enzyme 2 receptors to enter cells. This receptor is expressed on pancreatic beta cells and, during infection, it appears that receptor involvement may induce hyperglycemia in patients with or without diabetes. In this study, we discuss the mechanisms underlying the poor prognosis in people with COVID-19 and diabetes and what may improve the outcome in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.